消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 EHTG_ESCP指南：林奇综合征（更新版）

2021-05-27 欧洲肛肠病学学会 Br J Surg.2021 May 27;108(5):484-498.

林奇综合征

2021年5月，欧洲遗传性肿瘤小组(EHTG)联合欧洲肛肠病学学会(ESCP)共同发布了林奇综合征指南，林奇综合征是遗传下载最常见的遗传易感性，但诊断不足。本文主要针对林奇综合征的临床和分子诊断，林奇

中文标题：

2021 EHTG_ESCP指南：林奇综合征（更新版）

英文标题：

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

发布机构：

欧洲肛肠病学学会

发布日期：

2021-05-27

简要介绍：

2021年5月，欧洲遗传性肿瘤小组(EHTG)联合欧洲肛肠病学学会(ESCP)共同发布了林奇综合征指南，林奇综合征是遗传下载最常见的遗传易感性，但诊断不足。本文主要针对林奇综合征的临床和分子诊断，林奇综合征相关结直肠癌的外科和内镜下治疗以及癌症预防措施等内容提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 EHTG_ESCP指南：林奇综合征（更新版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c41e31c00211eaa1, title=2021 EHTG_ESCP指南：林奇综合征（更新版）, enTitle=European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender, guiderFrom=Br J Surg.2021 May 27;108(5):484-498., authorId=0, author=, summary=2021年5月，欧洲遗传性肿瘤小组(EHTG)联合欧洲肛肠病学学会(ESCP)共同发布了林奇综合征指南，林奇综合征是遗传下载最常见的遗传易感性，但诊断不足。本文主要针对林奇综合征的临床和分子诊断，林奇, cover=https://img.medsci.cn/2021628/1624851194766_2020535.jpg, journalId=0, articlesId=null, associationId=1880, associationName=欧洲肛肠病学学会, associationIntro=, copyright=0, guiderPublishedTime=Thu May 27 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年5月，欧洲遗传性肿瘤小组(EHTG)联合欧洲肛肠病学学会(ESCP)共同发布了林奇综合征指南，林奇综合征是遗传下载最常见的遗传易感性，但诊断不足。本文主要针对林奇综合征的临床和分子诊断，林奇综合征相关结直肠癌的外科和内镜下治疗以及癌症预防措施等内容提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2063, tagName=林奇综合征)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2063, guiderKeyword=林奇综合征, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5229, appHits=104, showAppHits=0, pcHits=894, showPcHits=5125, likes=1, shares=8, comments=8, approvalStatus=1, publishedTime=Mon Jun 28 17:51:27 CST 2021, publishedTimeString=2021-05-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Jun 28 11:33:22 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:43:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EHTG_ESCP指南：林奇综合征（更新版）.pdf)])
2021 EHTG_ESCP指南：林奇综合征（更新版）.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2107264, encodeId=362b210e264a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efc51400240, createdName=63955575, createdTime=Sat Dec 24 10:47:28 CST 2022, time=2022-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1000193, encodeId=36ca1000193db, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb9e1450537, createdName=412854774, createdTime=Fri Jul 16 22:02:24 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977946, encodeId=25fb9e794635, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ec5456064, createdName=ccoffer, createdTime=Tue Jun 29 15:54:53 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977942, encodeId=0f7a9e7942bd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/3ab38d52b3134c1ab3a438af0b2aaa85/70336983a9924c25ab80431b0dc8c320.jpg, createdBy=c50c5196369, createdName=147299b2m08暂无昵称, createdTime=Tue Jun 29 15:48:01 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977733, encodeId=48cc9e773362, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b135534037, createdName=咏隆, createdTime=Mon Jun 28 22:22:03 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2022-12-24 63955575 来自广东省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2107264, encodeId=362b210e264a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efc51400240, createdName=63955575, createdTime=Sat Dec 24 10:47:28 CST 2022, time=2022-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1000193, encodeId=36ca1000193db, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb9e1450537, createdName=412854774, createdTime=Fri Jul 16 22:02:24 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977946, encodeId=25fb9e794635, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ec5456064, createdName=ccoffer, createdTime=Tue Jun 29 15:54:53 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977942, encodeId=0f7a9e7942bd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/3ab38d52b3134c1ab3a438af0b2aaa85/70336983a9924c25ab80431b0dc8c320.jpg, createdBy=c50c5196369, createdName=147299b2m08暂无昵称, createdTime=Tue Jun 29 15:48:01 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977733, encodeId=48cc9e773362, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b135534037, createdName=咏隆, createdTime=Mon Jun 28 22:22:03 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-07-16 412854774

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2107264, encodeId=362b210e264a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efc51400240, createdName=63955575, createdTime=Sat Dec 24 10:47:28 CST 2022, time=2022-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1000193, encodeId=36ca1000193db, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb9e1450537, createdName=412854774, createdTime=Fri Jul 16 22:02:24 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977946, encodeId=25fb9e794635, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ec5456064, createdName=ccoffer, createdTime=Tue Jun 29 15:54:53 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977942, encodeId=0f7a9e7942bd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/3ab38d52b3134c1ab3a438af0b2aaa85/70336983a9924c25ab80431b0dc8c320.jpg, createdBy=c50c5196369, createdName=147299b2m08暂无昵称, createdTime=Tue Jun 29 15:48:01 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977733, encodeId=48cc9e773362, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b135534037, createdName=咏隆, createdTime=Mon Jun 28 22:22:03 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-29 ccoffer

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2107264, encodeId=362b210e264a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efc51400240, createdName=63955575, createdTime=Sat Dec 24 10:47:28 CST 2022, time=2022-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1000193, encodeId=36ca1000193db, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb9e1450537, createdName=412854774, createdTime=Fri Jul 16 22:02:24 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977946, encodeId=25fb9e794635, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ec5456064, createdName=ccoffer, createdTime=Tue Jun 29 15:54:53 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977942, encodeId=0f7a9e7942bd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/3ab38d52b3134c1ab3a438af0b2aaa85/70336983a9924c25ab80431b0dc8c320.jpg, createdBy=c50c5196369, createdName=147299b2m08暂无昵称, createdTime=Tue Jun 29 15:48:01 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977733, encodeId=48cc9e773362, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b135534037, createdName=咏隆, createdTime=Mon Jun 28 22:22:03 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-29 147299b2m08暂无昵称

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2107264, encodeId=362b210e264a9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efc51400240, createdName=63955575, createdTime=Sat Dec 24 10:47:28 CST 2022, time=2022-12-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1000193, encodeId=36ca1000193db, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb9e1450537, createdName=412854774, createdTime=Fri Jul 16 22:02:24 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977946, encodeId=25fb9e794635, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ec5456064, createdName=ccoffer, createdTime=Tue Jun 29 15:54:53 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977942, encodeId=0f7a9e7942bd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210629/3ab38d52b3134c1ab3a438af0b2aaa85/70336983a9924c25ab80431b0dc8c320.jpg, createdBy=c50c5196369, createdName=147299b2m08暂无昵称, createdTime=Tue Jun 29 15:48:01 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977733, encodeId=48cc9e773362, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b135534037, createdName=咏隆, createdTime=Mon Jun 28 22:22:03 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-28 咏隆

    学习

    0

相关指南

2019 ESGE指南：林奇综合征以及结直肠癌家族风险的内镜管理

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2019-10-09

2019 曼彻斯特国际共识组建议：林奇综合征妇科肿瘤的管理

国外肿瘤科相关专家小组（统称） · 2019-03-28

2017 ASCRS临床实践指南：林奇综合征患者的手术治疗

美国结肠和直肠外科医师学会(ASCRS,American Society of Colon and Rectal Surgeons) · 2017-01-01

2015 AGA指南：林奇综合征的诊断和管理

美国胃肠病协会(AGA,American Gastroenterological Association) · 2015-07-27

2015 ACG临床指南：遗传性胃肠道肿瘤综合征的管理和基因检测

美国胃肠病学院(ACG,American College of Gastroenterology) · 2015-02-03

2014 USMSTF共识声明：林奇综合征的遗传评估和管理指南

美国结直肠癌多学会工作组(USMSTF,US Multi-Society Task Force on Colorectal Cancer) · 2014-07-20

拓展阅读

2014 USMSTF共识声明：林奇综合征的遗传评估和管理指南

美国结直肠癌多学会工作组(USMSTF,US Multi-Society Task Force on Colorectal Cancer) · 2014-07-20

2015 ACG临床指南：遗传性胃肠道肿瘤综合征的管理和基因检测

美国胃肠病学院(ACG,American College of Gastroenterology) · 2015-02-03

2015 AGA指南：林奇综合征的诊断和管理

美国胃肠病协会(AGA,American Gastroenterological Association) · 2015-07-27

2017 ASCRS临床实践指南：林奇综合征患者的手术治疗

美国结肠和直肠外科医师学会(ASCRS,American Society of Colon and Rectal Surgeons) · 2017-01-01

2019 曼彻斯特国际共识组建议：林奇综合征妇科肿瘤的管理

国外肿瘤科相关专家小组（统称） · 2019-03-28

2019 ESGE指南：林奇综合征以及结直肠癌家族风险的内镜管理

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2019-10-09